Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 10/20 | 0.65 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | FPR2 | P25090 | 1/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8513782 | 0.89 | FPR2 (0.70) | CA1CA12CA9FPR2CTSL | |
| SCHEMBL8513785 | 0.89 | FPR2 (0.70) | CA1CA12CA9FPR2CTSL | |
| SCHEMBL20277616 | 0.87 | HPGDS (0.71) | HPGDSCA1CA12CA9CTSL | |
| SCHEMBL17244326 | 0.87 | HPGDS (0.71) | HPGDSCA1CA12CA9CTSL | |
| SCHEMBL27002688 | 0.86 | HPGDS (0.65) | HPGDSCA1CA12CA9CTSL | |
| SCHEMBL2105972 | 0.86 | HPGDS (0.65) | HPGDSCA1CA12CA9CTSL | |
| SCHEMBL12320657 | 0.83 | HPGDS (0.64) | HPGDSCA1CA12CA9PTPN1 | |
| SCHEMBL27695921 | 0.83 | HPGDS (0.65) | HPGDSCA1CA12CA9CTSL | |
| SCHEMBL4684065 | 0.83 | HPGDS (0.65) | HPGDSCA1CA12CA9CTSL | |
| SCHEMBL5926493 | 0.83 | PTPN1 (0.62) | CA1FPR2CTSLPTPN1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9463451-B2 | Ligand, metal complex containing ligand, and reaction using metal complex containing ligand | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2016-10-11 | — | — | US | disclosed |
| US-20160107151-A1 | LIGAND, METAL COMPLEX CONTAINING LIGAND, AND REACTION USING METAL COMPLEX CONTAINING LIGAND | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160107151-A1 | LIGAND, METAL COMPLEX CONTAINING LIGAND, AND REACTION USING METAL COMPLEX CONTAINING LIGAND | HRH3, HRH2, HRH4 | HPGDS 3511/4885CA1 2545/4885CA12 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.